文献速递垂体与肾上腺疾病性腺与生殖内分泌

改良释放氢化可的松改善先天性肾上腺皮质增生症女性生育力

Modified-Release Hydrocortisone for Female Fertility in Congenital Adrenal Hyperplasia.
PubMed 文献 · J Clin Endocrinol Metab · 2026-07-28

这项前瞻性病例系列纳入8例经典先天性肾上腺皮质增生症女性,因月经不规律或常规糖皮质激素治疗下仍未实现生育(中位4年,含辅助生殖)而换用改良释放氢化可的松。换药后晨间孕酮、17羟孕酮、雄烯二酮和睾酮中位浓度均下降,所有患者月经周期恢复规律,5例备孕者均在中位9.8个月内受孕,共6例健康活产和1例早期流产。

要点

  • 换用改良释放氢化可的松后激素控制改善且氢化可的松等效剂量更低
  • 所有患者月经周期恢复规律,备孕者均实现受孕
  • circadian优化糖皮质激素治疗或改变CAH女性生育管理范式

核心结论

  • 改良释放氢化可的松改善激素控制,与月经周期恢复及高自然受孕率相关,且氢化可的松等效剂量更低。

研究设计与样本

  • 前瞻性病例系列,纳入8例经典先天性肾上腺皮质增生症女性,因月经不规律或常规糖皮质激素治疗下未实现生育(中位4年,含辅助生殖)而换用改良释放氢化可的松。

主要发现

  • 换药后晨间血清孕酮中位浓度0.9 vs 2.1 ng/mL(2.9 vs 6.7 nmol/l),17羟孕酮49.0 vs 131.5 ng/dl(1.5 vs 4.0 nmol/l)。
  • 换药后晨间血清雄烯二酮中位浓度76.0 vs 261.0 ng/dL(2.7 vs 9.1 nmol/l),睾酮27.0 vs 63.0 ng/dL(0.9 vs 2.2 nmol/l)。
  • 氢化可的松等效剂量中位30.0 vs 32.5 mg/d,唾液17羟孕酮曲线下面积中位183.9 vs 676.5 pg×t(n)/mL且各时间点浓度更低。
  • 所有患者月经周期恢复规律;5例备孕者均在中位9.8个月内受孕,另发生2例非计划妊娠。
  • 结局包括6例健康活产和1例早期流产。

临床怎么用

  • 对常规糖皮质激素治疗下仍有月经紊乱或生育困难的经典CAH女性,可考虑换用改良释放氢化可的松以优化昼夜节律并改善生育结局。

局限性

  • 为前瞻性病例系列,样本量仅8例,无对照组,结果需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Women with classic congenital adrenal hyperplasia (CAH) suffer from reduced fecundity and fertility. This study aimed to assess fertility outcomes following treatment with modified-release hydrocortisone (MRHC), which more closely replicates the physiological circadian cortisol rhythm. METHODS: In this prospective case series, eight women with classic CAH and either menstrual irregularities or an unfulfilled desire to have children despite conventional GC therapy for a median duration of four years, including assisted reproduction, were switched to MRHC. Hormonal parameters, including morning serum progesterone, 17-hydroxyprogesterone (17OHP), androstenedione, testosterone, as well as daily salivary 17OHP profiles, were assessed before and after the switch. Clinical outcomes included menstrual cycle regularity and pregnancy. RESULTS: Descriptive analysis of morning serum samples indicate lower median concentrations of progesterone (0.9 vs. 2.1 ng/mL [2.9 vs. 6.7 nmol/l]), 17OHP (49.0 vs. 131.5 ng/dl [1.5 vs. 4.0 nmol/l]), androstenedione (76.0 vs. 261.0 ng/dL [2.7 vs. 9.1 nmol/l]), and testosterone (27.0 vs. 63.0 ng/dL [0.9 vs. 2.2 nmol/l]) after switching to MRHC with a lower median hydrocortisone dose equivalent (HDE) (30.0 v. 32.5 mg/d). Salivary 17OHP profiles showed a trend towards lower median AUC (183.9 vs. 676.5 pg×t(n)/mL) and lower concentrations across all time points. Regular menstrual cycles were restored in all patients. All five women seeking pregnancy conceived within a median of 9.8 months. Two unintended pregnancies occurred. Outcomes included six healthy live births and one early miscarriage. CONCLUSION: MRHC improved hormonal control and was associated with restoration of menstrual cyclicity and high rates of spontaneous conception with a lower HDE. Circadian optimization of GC therapy by MRHC may represent a paradigm shift in fertility management in females with CAH.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tschaidse L, Nowotny HF, Auer MK, et al. Modified-Release Hydrocortisone for Female Fertility in Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. 2026. PMID: 42517565. doi:10.1210/clinem/dgag303

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。